​

Funding Round

Series B - Scribe Therapeutics

Series B - Scribe Therapeutics

Investment Firm

Overview

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Announced Date

Mar 31, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Avoro Capital Advisors

Avoro Capital Advisors

Avoro Capital Advisors is a post_ipo and private_equity firm.

Participant Investors

8

Investor Name
Participant InvestorOrbiMed
Participant InvestorT. Rowe Price
Participant InvestorMenlo Ventures
Participant InvestorAndreessen Horowitz
Participant InvestorWellington Management

Round Details and Background

Scribe Therapeutics raised $100000000 on 2021-03-31 in Series B

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 01, 2018
Series A - Scribe Therapeutics
1-20.0M
Mar 31, 2021
Series B - Scribe Therapeutics
9-100.0M
May 17, 2023
Convertible Note - Scribe Therapeutics
1-undefined

Recent Activity

There is no recent news or activity for this profile.